التفاصيل البيبلوغرافية
| العنوان: |
Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion |
| المؤلفون: |
An-guo Chen, Dong-sheng Chen, Si Li, Le-le Zhao, Ming-zhe Xiao |
| المصدر: |
Frontiers in Oncology, Vol 12 (2022) |
| بيانات النشر: |
Frontiers Media S.A., 2022. |
| سنة النشر: |
2022 |
| المجموعة: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: |
ROS1 fusion, crizotinib, adjuvant treatment, NSCLC, case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: |
Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed randomized controlled trial. Next-generation sequencing (NGS) and immunohistochemistry (IHC) staining were performed on the biopsy sample. In this case, we identified a novel LDLR–ROS1 fusion in a resectable stage IIIA NSCLC patient. The patient received crizotinib as adjuvant treatment and achieved recurrence-free survival (RFS) for 29 months, without significant symptoms of toxicity. In this case, we report a novel LDLR–ROS1 fusion responding to crizotinib in a patient with lung adenocarcinoma, supporting the use of adjuvant treatment with the ROS1 inhibitor exerting clinical survival benefit in ROS1 fusion-positive resected NSCLC. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2234-943X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fonc.2022.837219/full; https://doaj.org/toc/2234-943X |
| DOI: |
10.3389/fonc.2022.837219 |
| URL الوصول: |
https://doaj.org/article/1edd8d77d09b40fdad59a45edff5b622 |
| رقم الانضمام: |
edsdoj.1edd8d77d09b40fdad59a45edff5b622 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder